Emerging invasive fungal diseases in transplantation

Current Infectious Disease Reports

Volumn 14, Issue 6, 2012, Pages 668-675

  Parize, Perrine ^a   Rammaert, Blandine ^a   Lortholary, Olivier ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Health care associated infection; Mucormycosis; Pneumocystis pneumonia; Solid organ transplantation .Hematopoietic stem cell transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; DEFERASIROX; ECHINOCANDIN; FLUCYTOSINE; FLUORODEOXYGLUCOSE F 18; ISAVUCONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FUNGUS TRANSMISSION; FUSARIOSIS; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; LUNG INFECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE INFECTION; PSEUDALLESCHERIASIS; REVIEW; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

EID: 84870565966     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0296-y     Document Type: Review

References (67)

1. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mouldrelated diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:i5-i14.
2. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101-11. A major cohort study assessing the overall and organ-specific burden of invasive fungal infections among transplants recipients.
3. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091-100. A major prospective study reporting epidemiologic trends of invasive fungal diseases in hematopoietic stem cell transplant recipients.
4. Lanternier F, Sun H-Y, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54:1-8. A recent literature review in addition to authors' perspectives on mucormycosis occurring in transplant recipients.
5. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerging Infect Dis. 2011;17:1855-64.
6. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 21199154. Accessed 2 March 2011.
7. Lanternier F, Dannaoui E, Morizot G, et al. A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54:S35-43.
8. Spellberg B, Kontoyiannis DP, Fredricks D, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22435877. Accessed 22 May 2012.
9. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715-22.
10. Zaoutis TE, Webber S, Naftel DC, et al. Invasive fungal infections in pediatric heart transplant recipients: incidence, risk factors, and outcomes. Pediatr Transplant. 2011;15:465-9.
11. Ng B, Dipchand A, Naftel D, et al. Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. Pediatr Transplant. 2011;15:844-8.
12. Däbritz J, Attarbaschi A, Tintelnot K, et al. Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. Mycoses. 2011;54:e785-8.
13. Rammaert B, Lanternier F, Zahar J-R, et al. Healthcare-Associated Mucormycosis. Clin Infect Dis. 2012;54:S44-54.
14. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis. 2010;51:259-65.
15. European best practice guidelines for renal transplantation. Section IV: Long-Term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 2002; 17 Suppl 4:36-39.
16. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S227-33.
17. Phipps LM, Chen SC-A, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation. 2011;92:1327-34.
18. de Boer MGJ, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13:559-69. A study reviewing 16 recent outbreaks of Pneumocystis jirovecii pneumonia in kidney recipients and describing epidemiological characteristics and clinical risk factors for the disease.
19. Emergence of Cryptococcus gattii-Pacific Northwest, 2004-2010. Am. J. Transplant. 2011;11:1989-1992. An article that analyzes the occurrence of two major cryptococcal outbreaks in North America.
20. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia. Canada Emerging Infect Dis. 2011;17:193-9.
21. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2011;53:1188-95.
22. Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 2000;343:1163-6.
23. Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis. 2003;37:1265-9.
24. Mueller NJ, Weisser M, Fehr T, et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis. 2010;12:54-9.
25. Albano L, Bretagne S, Mamzer-Bruneel M-F, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48:194-202.
26. Baddley JW, Schain DC, Gupte AA, et al. Transmission of Cryptococcus neoformans by Organ Transplantation. Clin Infect Dis. 2011;52:e94-8.
27. Fishman JA, Greenwald MA, Grossi PA. Transmission of Infection With Human Allografts: Essential Considerations in Donor Screening. Clin Infect Dis 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22670038. Accessed 17 July 2012.
28. Greenwald MA, Kuehnert MJ, Fishman JA. Infectious Disease Transmission during Organ and Tissue Transplantation. Emerging Infect Dis. 2012;18:e1.
29. Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409-17. The first prospective study on PET scan in various invasive fungal diseases.
30. Schmidt S, Tramsen L, Perkhofer S, et al. Characterization of the Cellular Immune Responses to Rhizopus oryzae With Potential Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation. J Infect Dis 2012; Available at: http://www.ncbi.nlm.nih.gov/pubmed/22529315. Accessed 22 May 2012.
31. Schrödl W, Heydel T, Schwartze VU, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-Assisted laser desorption ionization-Time of flight analyzer-mediated mass spectrometry. J Clin Microbiol. 2012;50:419-27.
32. Coulibaly O, Marinach-Patrice C, Cassagne C, Piarroux R, Mazier D, Ranque S. Pseudallescheria/Scedosporium complex species identification by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry. Med Mycol. 2011;49:621-6.
33. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49: 2151-3.
34. Babady NE, Miranda E, Gilhuley KA. Evaluation of Luminex xTAG fungal analyte-specific reagents for rapid identification of clinically relevant fungi. J Clin Microbiol. 2011;49:3777-82.
35. Steinmann J, Schmidt D, Buer J, Rath P-M. Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequencebased PCR. Med Mycol. 2011;49:475-83.
36. Lu Q, Gerrits van den Ende AH, Bakkers JM, et al. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J Clin Microbiol. 2011;49:960-7.
37. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21.
38. Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and metaanalysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633-43. A meta-Analysis reporting the performance of BG antigenemia assays for the diagnosis of invasive fungal infections in patients with hematological malignancies.
39. de Boer MGJ, Gelinck LBS, van Zelst BD, et al. β-D-glucan and S-Adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect. 2011;62:93-100.
40. Costa J-M, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association Between Circulating DNA, Serum (1->3)-β-D-Glucan, and Pulmonary Fungal Burden in Pneumocystis Pneumonia. Clin Infect Dis. 2012;55:e5-8.
41. Hauser PM, Bille J, Lass-Flörl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-Time PCR assay. J Clin Microbiol. 2011;49:1872-8.
42. Kontoyiannis DP, Lewis RE, Lotholary O, et al. Future directions in mucormycosis research. Clin Infect Dis. 2012;54 Suppl 1:S79-85.
43. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216-24.
44. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother. 2011;55:3584-7.
45. Ibrahim AS, Gebremariam T, Luo G, et al. Combination Therapy of Murine Mucormycosis or Aspergillosis with Iron Chelation, Polyenes and Echinocandins.Antimicrob Agents Chemother 2011;Available at: http://www.ncbi.nlm.nih.gov/pubmed/21263057. Accessed 2 March 2011.
46. Drogari-Apiranthitou M, Mantopoulou F-D, Skiada A, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012;67:1937-40.
47. Vigouroux S,Morin O,Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005;40:e35-7.
48. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-Active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-60.
49. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348-55.
50. Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood. 2011;118:5416-9.
51. Kontoyiannis DP. Deferasirox lacks in vitro activity against Fusarium and Scedosporium species and black molds. Virulence. 2011;2:257-8.
52. Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses. 2011;54 Suppl 3:12-21.
53. Spader TB, Venturini TP, Cavalheiro AS, et al. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses. 2011;54:131-6.
54. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446-50.
55. Persy B, Vrelust I, Gadisseur A, Ieven M. Phialemonium curvatum fungaemia in an immunocompromised patient: case report. Acta Clin Belg. 2011;66:384-6.
56. Choi J, Lee Y, Chung H-S, et al. Subcutaneous phaeohyphomycosis caused by Phaeoacremonium species in a kidney transplant patient: the first case in Korea. Korean J Lab Med. 2011;31:201-4.
57. Miossec C, Morio F, Lepoivre T, et al. Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol. 2011;49:2743-7.
58. Pelegrín I, Ayats J, Xiol X, et al. Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review. Transpl Infect Dis. 2011;13:507-14.
59. Rosow L, Jiang JX, Deuel T, et al. Cerebral phaeohyphomycosis caused by Bipolaris spicifera after heart transplantation. Transpl Infect Dis. 2011;13:419-23.
60. Lief MH, Caplivski D, Bottone EJ, Lerner S, Vidal C, Huprikar S. Exophiala jeanselmei infection in solid organ transplant recipients: report of two cases and review of the literature. Transpl Infect Dis. 2011;13:73-9.
61. Zhang Y-Q, Xu X-G, Li F-Q, Wei H, Chen H-D, Li Y-H. Coexistence of cutaneous alternariosis and tinea corporis in a renal transplant recipient. Med Mycol. 2011;49:435-8.
62. Rammaert B, Aguilar C, Bougnoux M-E, et al. Success of posaconazole therapy in a heart transplanted patient with Alternaria infectoria cutaneous infection. Med. Mycol. 2011; Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 22142219. Accessed 2 April 2012.
63. Vignon M, Michonneau D, Baixench M-T, et al. Disseminated Scopulariopsis brevicaulis infection in an allogeneic stem cell recipient. Bone Marrow Transplant. 2011;46:1276-7.
64. Ryan LJ, Ferrieri P, Powell Jr RD, Paddock CD, Zaki SR, Pambuccian SE. Fatal Cokeromyces recurvatus pneumonia: report of a case highlighting the potential for histopathologic misdiagnosis as coccidioides. Int J Surg Pathol. 2011;19:373-6.
65. Spellberg B, Ibrahim A, Roilides E, et al. Combination Therapy for Mucormycosis: Why, What, and How? Clin Infect Dis. 2012;54: S73-8.
66. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125:S25-38.
67. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743-50.